SpyBiotech Limited

SpyBiotech is a clinical-stage vaccine platform company that utilises the proprietary SpyTag/SpyCatcher protein "superglue" technology to rapidly and precisely attach disease antigens to vaccine delivery vehicles, creating stable and highly immunogenic vaccines for infectious diseases and cancer.

SpyBiotech's core offering is its 'plug and display' vaccine platform, rooted in the SpyTag/SpyCatcher technology—a system derived from a bacterial protein that spontaneously forms an irreversible, covalent (covalent) bond between two components, acting as a "protein superglue." This highly stable bond allows the company to efficiently decorate the surface of vaccine carriers, such as Virus-Like Particles (VLPs), with a high and precise density of target antigens. This simplified, irreversible conjugation process overcomes the limitations of traditional, complex manufacturing methods, resulting in vaccines that are not only easier to produce and more stable against temperature fluctuations (improving global access) but are also designed to elicit a more robust and potent neutralizing antibody response against a wide range of pathogens and therapeutic targets, including their lead candidate for Human Cytomegalovirus (HCMV).

• Oncology